• Gene fusion; HGNC; HGNC:427; ALK + HGNC; HGNC:1316; EML4; Name(s)=EML4-ALK (from parent cell line).
  

PubMed=21502504; DOI=10.1073/pnas.1019559108; PMCID=PMC3088626
Ryohei Katayama, Tahsin M. Khan, Cyril Henri Benes, Eugene Lifshits, Hiromichi Ebi, Victor M. Rivera, William C. Shakespeare, Anthony John Iafrate, Jeffrey Adam Engelman, Alice Tsang Shaw;
Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALK.
Proc. Natl. Acad. Sci. U.S.A. 108:7535-7540(2011)

PubMed=23344087; DOI=10.1097/JTO.0b013e318283dcc0
Soyeon Kim, Tae Min Kim, Dong-Wan Kim, Heounjeong Go, Bhumsuk Keam, Se-Hoon Lee, Ja-Lok Ku, Doo Hyun Chung, Dae Seog Heo;
Heterogeneity of genetic changes associated with acquired crizotinib resistance in ALK-rearranged lung cancer.
J. Thorac. Oncol. 8:415-422(2013)

PubMed=24675041; DOI=10.1158/2159-8290.CD-13-0846; PMCID=PMC4068971
Luc Friboulet, Nan-Xin Li, Ryohei Katayama, Christian C. Lee, Justin Franklin Gainor, Adam S. Crystal, Pierre-Yves Michellys, Mark M. Awad, Noriko Yanagitani, Sungjoon Kim, AnneMarie Culazzo Pferdekamper ...Show all 24 authors... , Jie Li, Shailaja Kasibhatla, Frank Sun, Xiu-Ying Sun, Su Hua, Peter McNamara, Sidra Mahmood, Elizabeth L. Lockerman, Naoya Fujita, Makoto Nishio, Jennifer L. Harris, Alice Tsang Shaw, Jeffrey Adam Engelman; Show fewer authors
The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer.
Cancer Discov. 4:662-673(2014)